NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

Browse:
anti-HER2/Anti-CD3 bispecific monoclonal antibody BTRC 4017A
An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 T-cell-dependent bispecific (TDB) monoclonal antibody with potential immunostimulatory and antineoplastic activities. Upon administration, anti-HER2/anti-CD3 bispecific monoclonal antibody BTRC4017A possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of BTRC4017A, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:anti-HER2 x anti-CD3 bispecific monoclonal antibody BTRC 4017A
anti-HER2 x anti-CD3 bispecific monoclonal antibody RG 6194
anti-HER2/anti-CD3 bispecific monoclonal antibody 4017A
Code name:ARG-6194
BTRC 4017A
BTRC-4017
BTRC4017A
RG 6194
RG6194